-
In the current study, metabolic syndrome and abnormal metabolic indexes in untreated patients with BDs were observed utilising diagnostic criteria specifically designed for the Chinese population.
-
Weight management, regular monitoring, and appropriate exercise and dietary interventions were suggested for patients with BDs.
-
No significant differences were found in the incidence of metabolic indexes and abnormal metabolic indexes between patients with depressive and manic episodes.
-
Considering the cross-sectional nature of the current study, the association between seizure frequency, disorder severity, and the incidence of Mets could not be evaluated.
-
Lifestyle and dietary factors that may influence the prevalence of metabolic syndrome were not adequately accounted for.
-
The study population primarily consisted of individuals experiencing paroxysmal episodes, limiting the generalisability of the findings.
Introduction
Bipolar disorders (BDs) are frequently linked to increased morbidity and mortality rates. A meta-analysis published in JAMA Psychiatry in 2015 showed that the mortality rate of the condition was approximately 2 to 3 times higher than that of individuals without the disorder (Walker et al., Reference Walker, McGee and Druss2015). Several other related studies have also indicated that individuals with BDs have a shorter life expectancy of 10 to 11 years compared to the general population (Leboyer et al., Reference Leboyer, Soreca, Scott, Frye, Henry, Tamouza and Kupfer2012). This is mainly attributed to the presence of comorbid metabolic syndrome. Metabolic syndrome (Mets) is a complex metabolic disorder characterised by multiple risk factors such as obesity, hyperglycaemia, hypertension, and dyslipidaemia. It is considered to be a significant risk factor for diabetes, cardiovascular diseases, and cerebrovascular diseases. The global prevalence of Mets among adults was reported to be around 20 to 25% (Tanner et al., Reference Tanner, Brown and Muntner2012). However, the incidence of Mets was found to be even higher in individuals with BDs. According to a meta-analysis published in World Psychiatry in 2015, the prevalence of Mets in individuals with BDs was 31.7%. After adjusting for age and sex, individuals with BDs were found to have a 1.58-fold increased risk of developing Mets compared to controls (Vancampfort et al., Reference Vancampfort, Stubbs, Mitchell, de Hert, Wampers, Ward, Rosenbaum and Correll2015).
Based on several earlier studies conducted both domestically and internationally, the coexistence of metabolic syndrome and bipolar disorders was linked to the use of antipsychotic drugs (Bond et al., Reference Bond, Kauer-Sant’anna, Lam and Yatham2010; Arango et al., Reference Arango, Gir Ldez, N-Naranjo, Baeza, Castro-Fornieles, Alda, J., Mart Nez-Cantarero, Moreno, de Andr, Cuerda, de la Serna, Correll, C., Fraguas and Parellada2014). However, there is limited research available regarding the occurrence of metabolic syndrome, metabolism in various disease states, as well as risk factors among untreated individuals with BDs. Therefore, in this current study, we enrolled untreated individuals with BDs as participants with an attempt to evaluate the occurrence of metabolic syndrome and identify the associated risk factors.
Participants and methods
Participants
The current study included hospitalised patients with BDs at the Department of Psychiatry, the First Hospital of Hebei Medical University, between February 2016 and April 2017. The inclusion criteria were as follows: (1) individuals who met the diagnostic criteria of BDs according to the ICD-10 classification system; (2) aged between 18 and 65 years; (3) no history of using mood stabilisers, antipsychotics, or antidepressants. The exclusion criteria were as follows: (1) patients with metabolic disorders caused by serious somatic diseases such as endocrine diseases (e.g. hyperthyroidism or hypothyroidism), hepatitis, and digestive system diseases and (2) pregnant or lactating individuals.
The control group consisted of healthy individuals who underwent physical examinations at the First Hospital of Hebei Medical University during the same period.
Methods
Study protocol
Demographic data, metabolic data, and case characteristics of patients with BDs were collected.
Metabolic indexes
Body mass index (BMI): calculated as the ratio of weight (in Kilograms) to the square of height (in metres) (kg/m2) (Wysokiński et al., Reference Wysokiński, Strzelecki and Kłoszewska2015).
Blood pressure: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured after a 5-minute rest.
Blood lipids: triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C).
Blood glucose: fasting plasma glucose (FPG).
Diagnostic criteria of metabolic syndrome
The diagnostic criteria of metabolic syndrome in our study were based on the criteria established by the Diabetes Branch of Chinese Medical Association (2007), specifically tailored for the Chinese population. To meet the criteria, individuals should fulfil three or more following parameters: 1) overweight or obese: BMI ≥25 kg/m2; 2) FPG≥6.1 mmol/L, or 2-hour postprandial blood glucose ≥7.8 mmol/L, or a diagnosis of diabetes receiving treatment; 3) SBP/DBP ≥140/90 mmHg, or a diagnosis of hypertension; 4) TG levels ≥1. 7 mmol/L, or HDL-C: <0.91 mmol/L in males, <1.01mmol/L in females.
Statistical analysis
The present study applied the statistical software SPSS version 25.0 for conducting statistical analyses. The normality of continuous variables was assessed by a P-P diagram. Continuous variables were compared using t-test or nonparametric test, while categorical variables were compared using the Pearson chi-square test. A significance level of P < 0.05 was considered indicative of a statistically significant difference across the study.
Results
General demographic and clinical characteristics of the two groups
The BDs group consisted of a total of 125 patients, including 69 females (55.2%) and 56 males (44.8%), with an average age of 31.67 ± 11.85 years. Among the enrolled participants, 37 (29.6%) had depression, 75 (60%) were in a manic state, and 13 (10.4%) were in a mixed state. The median duration of the disorder was 1 month, and the average length of hospital stay was 26.75 ± 16.43 days. Notably, the average age of the control group was higher than that of the BDs group (36.75 ± 10.91 vs. 31.66 ± 11.85, P < 0.01, Table 1).
Comparison of metabolic parameters between the two groups
The SBP in the BDs group was found to be significantly higher compared to the control group (127.66 ± 16.21 vs. 122.67 ± 16.48, P < 0.01). Conversely, the HDL-C (1.13 ± 0.25 vs. 1.23 ± 0.30, P < 0.01) and total cholesterol (4.02 ± 0.90 vs. 4.45 ± 0.84, P < 0.01) in the BDs group were significantly lower than those in the control group. Nevertheless, no significant differences were observed in BMI, DBP, triglyceride, blood glucose, and LDL-C between the two groups. The incidence of Mets was slightly higher in the BDs group compared to the control group (9.6% vs. 8.5%, P = 0.658), but this difference failed to reach significant statistical significance. On the other hand, the incidence of abnormal blood glucose (≥6.1 mmol/L) was associated with higher outcomes in the BDs group compared to the control group (11.6% vs. 2.5%, P < 0.01), whereas the incidence of abnormal BMI (BMI ≥25 kg/m2) showed otherwise in the BDs group when comparing to the control group (24% vs. 28.5%, P < 0.01). After adjusting for sex and age, there were significant differences in the incidence of Mets (P < 0.01) and abnormal SBP (SBP ≥140 mmHg) between the two groups. However, no significant difference was seen in the incidence of abnormal BMI between the two groups (P = 0.288) (Tables 2 and 3).
Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol; FPG: fasting plasma glucose; TC: total cholesterol; LDL-C: low-density lipoprotein-cholesterol; Mets: metabolic syndrome.
Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol; FPG: fasting plasma glucose; TC: total cholesterol; LDL-C: low-density lipoprotein-cholesterol; Mets: metabolic syndrome.
Risk factors for metabolic syndrome in patients with BDs
The SBP (133.70 ± 13.73 vs. 122.77 ± 16.49, p < 0.01) and triglyceride levels (1.04 (0.62) vs. 0.75 (0.53), P < 0.01) were higher in males compared to females. Additionally, the level of HDL-C was significantly lower in males than in females. However, no significant differences were seen between males and females in terms of BMI, DBP, blood glucose, total cholesterol, and LDL-C. The incidence of metabolic syndrome was higher in males compared to females (14.5% vs. 5.8%, P = 0.102). Males also had a higher incidence of meeting at least two diagnostic criteria for Mets compared to females (33.9% vs. 17.4% P < 0.05). Moreover, the incidence of abnormal triglyceride levels (TG≥1.7 mmol/L) was higher in males when compared to females, but there were no significant differences in the incidence of abnormal metabolic indexes between the sexes (Table 4).
Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol; FPG: fasting plasma glucose; TC: total cholesterol; LDL-C: low-density lipoprotein-cholesterol; Mets: metabolic syndrome.
Discussion
In recent years, there has been an increasing focus on research related to comorbid mental diseases, particularly metabolic and endocrine disorders, including metabolic syndrome. The natural occurrence or underlying causes of metabolic syndrome are still not fully understood. In the current study, the presence of metabolic syndrome and abnormal metabolic indexes in untreated patients with BDs was examined using diagnostic criteria specifically designed for the Chinese population. The findings revealed a high incidence of metabolic syndrome in untreated patients with BDs compared to controls, which was consistent with the results reported by Anjum et al.(Anjum et al., Reference Anjum, Bathla and Panchal2019) and a meta-analysis published in World Psychiatry in 2015 (Vancampfort et al., Reference Vancampfort, Stubbs, Mitchell, de Hert, Wampers, Ward, Rosenbaum and Correll2015). However, the incidence of Mets in patients with BDs observed in our study was relatively lower than that reported in other studies, such as the study conducted by Shazia Anjum, which reported a 33.33% occurrence of Mets among BD patients (Kumar et al., Reference Kumar, Narayanaswamy, Venkatasubramanian, Raguram, Grover and Aswath2017). Additionally, a related study conducted in China reported a comorbidity rate of 25.7% for Mets, significantly higher than that in the control group (9.6%)(Xiang et al., Reference Xiang, Mao and Zhao2017). Several reasons may account for these results. First of all, the patients included in this had a relatively short duration of the disorder, with a median of 1 month, and none of them had received any psychiatric drug treatment. Secondly, the diagnostic criteria used in this study differed from those used in other studies, as most studies assess obesity based on waist circumference, whereas our study utilised BMI. Lastly, the average age of the participants in our study was relatively young (31.67 ± 11.85 years). Nevertheless, these factors (i.e. young age and short duration of the disorder) actually highlighted the susceptibility of patients with BDs to comorbid metabolic syndrome. Potential pathophysiological mechanisms contributing to this association may include hyperactivity of the hypothalamus-pituitary-adrenal axis and sympathetic medulla, increased platelet response activity, decreased heart rate variability, vascular inflammation, oxidative stress, and endothelial dysfunction (Goldstein et al., Reference Goldstein, Carnethon, Matthews, McIntyre, Miller, Raghuveer, Stoney, Wasiak and McCrindle2015). Based on earlier studies, the dysregulation of cortisol in patients with BDs is crucial for the development of core manifestations of Mets, such as hyperglycaemia, obesity, and dyslipidaemia (Kim et al., Reference Kim, Kim, McIntyre, Park, Kim and Joo2009).
According to the findings of this study, males exhibited a higher likelihood of developing metabolic syndrome compared to females. Although there was no statistical difference between the two groups, males had higher incidence of meeting at least two diagnostic criteria for metabolic syndrome. They also had higher triglyceride levels and a higher incidence of abnormal triglyceride levels compared to females. Additionally, the level of HDL-C, which plays a role in cholesterol reverse transcription, was lower in males than in females. However, a review by Anusha Baskaran demonstrated that females were more prone to developing abdominal obesity than males and controls(Baskaran et al., Reference Baskaran, Cha, Powell, Jalil and McIntyre2014). This discrepancy may be attributed to the following factors: 1) The average age of females in this study was relatively young (33.32 ± 11.82 years), and their oestrogen levels were relatively normal, thus minimising the impact on glucose and lipids metabolism. Conversely, the lack of oestrogen in males may lead to increased lipid levels, inducing insulin resistance and atherosclerosis (Regitz-Zagrosek et al., Reference Regitz-Zagrosek, Lehmkuhl and Mahmoodzadeh2007). 2) Males may tend to engage in unhealthy habits such as smoking and alcohol consumption. Moreover, females are more likely to adopt extreme measures, such as controlling their diet and increasing physical activity, in response to weight gain under social stress (Hong et al., Reference Hong, Chen, Yeh, Chu and Chen2015). Further investigation into the differences between males and females in different age groups can provide valuable insights.
The regression analysis conducted in this study revealed that age and BMI were independent risk factors responsible for Mets, which was consistent with the conclusions reported by Kumar, A. and Reda Roshdy et al.. They found that BDs patients with comorbid metabolic syndrome were older than those without comorbid metabolic syndrome, and the prevalence of Mets increased with age (Perugi et al., Reference Perugi, Quaranta, Belletti, Casalini, Mosti, Toni and Dell’Osso2015; Roshdy et al., Reference Roshdy, Abdelmawella and Bayoumy2017). BMI was identified as an independent risk factor for Mets, consistent with the findings of a study conducted in China. The study reported that individuals with healthy overweight (BMI 25–29.9) and obesity (BMI >30) had a higher risk of cardiovascular disorder and mortality compared to those with abnormal metabolism but normal weight (Fan et al., Reference Fan, Song, Chen, Hui and Zhang2013). Therefore, patients with BDs should pay also attention to changes in their weight and engage in regular weight monitoring, exercise, and maintain a balanced diet.
In terms of clinical manifestations, patients with depression are more likely to exhibit sedentary behaviour, while those experiencing manic episodes tend to be more active and energetic, leading to increased energy expenditure. It was observed that patients with depression had a higher likelihood of experiencing metabolic abnormalities compared to those with mania. However, our results did not show significant differences in the incidence of metabolic indexes and abnormal metabolic indexes between patients with depression and those with manic episodes. Hypothesis is that the comorbidity of Mets and BDs may be attributed to long-term intrinsic association between the two conditions, such as genetic associations (Lee et al., Reference Lee, Wray, Goddard and Visscher2011). Additionally, there may be a subtype of metabolic-affective syndrome (Mansur et al., Reference Mansur, Brietzke and McIntyre2015), suggesting that the relationship was not solely based on emotional states. Our results revealed that patients who met more than two diagnostic criteria for metabolic syndrome had a higher proportion of individuals with depression. However, it is important to note that this did not imply that patients with depression were linked to a higher incidence of metabolic syndrome compared to those with manic episodes. It should be taken into consideration that the sample size in our study was small, and the number of patients with manic episodes was significantly higher than that of patients with depression, potentially leading to type II errors. Therefore, further research with larger sample size is needed to confirm these findings.
Conclusion
In summary, individuals with bipolar disorders were found to have a significantly increased risk of developing metabolic syndrome. Factors such as male sex, age, and BMI were identified as potential contributing factors to the development of the metabolic syndrome in these individuals.
Acknowledgements
Not applicable.
Author contribution
Conceptualisation: Qianli Liu and Cuixia An.
Methodology: Qianli Liu, Lan Wang, Fengya Zhen, Cuixia An.
Data collection: Qianli Liu, Lan Wang, Fengya Zhen.
Writing – original draft preparation: Qianli Liu.
Writing – review and editing: Lan Wang, Fengya Zhen, Cuixia An.
Project administration and funding acquisition: Cuixia An.
The author(s) read and approved the final manuscript.
Financial support
This study was funded by National Science Foundation of Hebei Province (No. H2022206544) and Hebei Medical University ‘14th Five-Year’ Clinical Medicine Innovation Research Team Support Program (No.2022LCTD-A1).
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of First Hospital of Hebei Medical University. The research had been performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects
Consent for publication
Not applicable.